Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EffCaMgCit for PPI-Related Complications
NCT03812380Phase 3Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2019
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calcium citrate + magnesium citrate in osteoporosis, hypomagnesemia and chronic kidney disease (CKD) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoints: Bone Mineral Density T-Score at 2 years, Bone Mineral Density Z-Score at 2 years and 3 more. Started Jan 2019; status: terminated.
02
Drugs
calcium citrate + magnesium citrate
03
Conditions
osteoporosishypomagnesemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03812380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812380.